A very solid report, sales and EBIT in line A very solid report from G5 today.
Redeye reinforces its positive view of Proact following a strong Q4 report.
Redeye shares its preview of Devyser Diagnostics’ Q4 2022 results, due on February 21.
Q4 report in brief Svedbergs continued to show relative strength in a tough consumer market, with Q4...
Q4 results Q4 sales of SEK 4,687m (+2% vs. ABGSCe 4,596m), up 21% y-o-y.
Stark orderbok och fortsatt god orderingång Orderingång en för det fjärde kvartalet uppgick till 270...
2022 var ett starkt år trots utmaningar och marginalpress Nettoomsättningen steg med 11% till 261 mk...
Redeye takes a positive view of today’s news, where Westpay has entered an agreement that will enhan...
Fortsatt hög uthyrningsgrad och ökade driftöverskott Hyresintäkter i kvartalet uppgick till 8,5 mEUR...
Redeye adjusts our growth assumptions for 2023e and beyond, the Q4 report increases our conviction i...
Reached '22 guidance, but disappointing '23 guidance Proposed DPS of DKK 4.
Q4'22 pre-tax profit +2% vs. ABGSCe Positive signs on trading income and costs '23e-'24e 6% div.
CirChem publicerade den 7 februari bolagets delårsrapport för årets fjärde kvartal.
Q4 15% below us on EBITA, but Medical beat expectations Integrated the main driver of estimate downg...
Redeye comments on Annexin’s Q4 report, which came in as expected, and largely reiterate our view of...
Q4'22 pre-tax profit +2% vs ABGSC 2022 ended with a rebound in trading income Proposed DPS at DKK 0.
Raute reports Q4 results on Feb 14. There’s still haze around revenue and margins going forward, but...
Redeye will likely make minor forecast adjustments following Bredband2’s Q4 2022 report.
Redeye gives a comment on Xavi Solutions Q4 2022 report that was revealed earlier today.
Sales SEK 438m, -2% vs. ABGSCe Adj. EBITA SEK 54m, 3% vs ABGSCe On unrevised ests, share trading at ...
